Want to see ARMP full AI Analyst Report?

Armata Pharmaceuticals (ARMP) Price & Analysis

325 Followers

ARMP Stock Chart & Stats

$5.56

$0.06(1.29%)

At close: Jul 27 4:00 PM EDT

$5.56

$0.06(1.29%)

Day’s Range― - ―

52-Week Range$2.75 - $14.98

Previous CloseN/A

Volume56.99K

Average Volume (3M)296.81K

Market Cap

$135.34M

Enterprise Value$692.03M

Total Cash (Recent Filing)$23.95M

Total Debt (Recent Filing)$313.95M

Price to Earnings (P/E)―

Beta0.45

Next Earnings

Nov 18, 2026

EPS Estimate

-0.56

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.30

Shares Outstanding37,181,980

10 Day Avg. Volume110,611

30 Day Avg. Volume296,811

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-1.04

Price to Sales (P/S)46.41

P/FCF Ratio-8.65

Enterprise Value/Market Cap5.11

Enterprise Value/Revenue209.77

Enterprise Value/Gross Profit307.43

Enterprise Value/Ebitda-4.10

Forecast

1Y Price Target

$17.50

Price Target Upside214.75% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-2.62

Revenue Forecast (FY)$3.00M

Bulls Say, Bears Say

Bulls Say

Regulatory And Clinical ValidationBreakthrough Therapy designation and favorable early clinical results strengthen AP-SA02’s regulatory position and support accelerated FDA interaction. The reported higher and earlier cure rates, absence of drug-attributed serious adverse events, and relapse-free responses improve the program’s prospects.

Non-dilutive Development FundingAdditional government funding directly supports Phase 3 development while reducing the amount of near-term capital Armata must raise from investors. Continued federal backing also provides external validation of the program’s strategic importance in antibiotic-resistant infections.

Specialized Phage Therapeutics PlatformArmata’s focus on bacteriophage-based therapeutics addresses serious infections where antibiotic resistance creates substantial medical need. Its engineered and naturally derived candidates, together with phage development and manufacturing capabilities, provide a specialized platform for future programs.

Bears Say

Negative Equity And LeveragePersistent negative equity leaves Armata with limited balance-sheet flexibility and reduces its ability to absorb continued development losses. Meaningful debt increases financial strain, while the modest asset base provides a limited cushion if operating losses and funding requirements remain elevated.

Persistent Cash BurnOngoing negative operating and free cash flow shows that the business does not yet fund its activities internally. Continued cash consumption requires external capital to sustain clinical development, increasing financing dependence and the potential pressure on future capital allocation.

Pre-commercial Earnings ProfileArmata remains dependent on collaboration-related arrangements, funding, and external financing rather than commercial product sales. With revenue at a very small scale and operating costs far above current income, the company is still distant from sustainable earnings generation.

Armata Pharmaceuticals News

Armata announces two new patents covering bacteriophage programs

Armata Pharmaceuticals (ARMP) announced issuance of two patents by the U.S. Patent and Trademark Office, or USPTO, covering...

17d ago

ARMP

Armata secures new U.S. funding for AP-SA02 Phase 3

Armata Pharmaceuticals ( ($ARMP) ) has shared an announcement. On September 23, 2026, Armata Pharmaceuticals announced it received...

1M ago

ARMP

Armata Pharmaceuticals receives $3.7M in additional funding from DoW

Armata Pharmaceuticals (ARMP) announced that it has received an additional $3.7M in non-dilutive funds from the U.S. Department...

1M ago

ARMP

Armata wins FDA Breakthrough Therapy for AP-SA02

Armata Pharmaceuticals ( ($ARMP) ) just unveiled an update. On September 14, 2026, Armata Pharmaceuticals announced that the...

1M ago

ARMP

Armata Pharmaceuticals receives FDA Breakthrough Therapy Designation for AP-SA02

Armata Pharmaceuticals (ARMP) announced that the U.S. FDA has granted Breakthrough Therapy designation to AP-SA02, the company’s intravenously...

1M ago

ARMP

Armata Pharmaceuticals announces new published paper on Ar-KM

Armata Pharmaceuticals (ARMP) announced a paper in the Journal of Molecular Biology, a peer-reviewed journal. The publication, titled...

2M ago

ARMP

Analyst Maintains Buy on Armata as AP-SA02 Nears Phase 3, Backed by Regulatory Tailwinds and $20 DCF-Based Price Target

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on ARMP stock, giving a Buy rating on August...

2M ago

ARMP

Armata: Buy Rating Reiterated as AP-SA02 Advances Toward 2H26 Phase 3 Start; $15 Price Target Maintained

Armata Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

2M ago

ARMP

Armata Pharmaceuticals Promotes David House to CFO

An announcement from Armata Pharmaceuticals ( ($ARMP) ) is now available. On July 17, 2026, Armata Pharmaceuticals’ board...

3M ago

ARMP

Armata Advances AP-SA02 Toward Phase 3 Trial Launch

An update from Armata Pharmaceuticals ( ($ARMP) ) is now available. On July 20, 2026, Armata Pharmaceuticals reported...

3M ago

ARMP

Armata provides update on AP-SA02 studies

Armata Pharmaceuticals (ARMP) announced significant clinical, regulatory, manufacturing and operational progress supporting advancement of AP-SA02, the Company’s intravenously...

3M ago

ARMP

Armata promotes David House to CFO

Armata announced the promotion of David House to CFO. House has served as the Company’s Senior Vice President,...

3M ago

ARMP

FDA Pediatric Plan Milestone and Phase 3 Design Support Unchanged $15 Price Target and Buy Rating on Armata (ARMP)

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Armata Pharmaceuticals, retaining the price target of...

3M ago

ARMP

Armata Advances AP-SA02 Pediatric Plan With FDA Agreement

Armata Pharmaceuticals ( ($ARMP) ) has shared an announcement. On July 13, 2026, Armata Pharmaceuticals announced that the...

3M ago

ARMP

ARMP FAQ

What was Armata Pharmaceuticals Inc’s price range in the past 12 months?

Armata Pharmaceuticals Inc lowest stock price was $2.75 and its highest was $14.98 in the past 12 months.

What is Armata Pharmaceuticals Inc’s market cap?

Armata Pharmaceuticals Inc’s market cap is $135.34M.

When is Armata Pharmaceuticals Inc’s upcoming earnings report date?

Armata Pharmaceuticals Inc’s upcoming earnings report date is Nov 18, 2026 which is in 25 days.

How were Armata Pharmaceuticals Inc’s earnings last quarter?

Armata Pharmaceuticals Inc released its earnings results on Aug 12, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.445 by $0.175.

Is Armata Pharmaceuticals Inc overvalued?

According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Armata Pharmaceuticals Inc pay dividends?

Armata Pharmaceuticals Inc does not currently pay dividends.

What is Armata Pharmaceuticals Inc’s EPS estimate?

Armata Pharmaceuticals Inc’s EPS estimate is -0.56.

How many shares outstanding does Armata Pharmaceuticals Inc have?

Armata Pharmaceuticals Inc has 37,181,980 shares outstanding.

What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?

Armata Pharmaceuticals Inc reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.445. Following the earnings report the stock price went up 11.833%.

Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ARMP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Armata Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

89.70%

Trailing 12-Months

Asset Growth

11.34%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

Armata Pharmaceuticals (ARMP) Earnings & Revenues

Historic Earnings Reports

ARMP Stock 12 Month Forecast

Average Price Target

$17.50

▲(214.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.31,4.593846153846154,5.877692307692308,7.161538461538461,8.445384615384615,9.72923076923077,11.013076923076923,12.296923076923077,13.580769230769231,14.864615384615385,16.14846153846154,17.432307692307692,18.716153846153844,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.31,4.401538461538461,5.493076923076924,6.584615384615384,7.676153846153847,8.767692307692307,9.85923076923077,10.95076923076923,12.042307692307693,13.133846153846156,14.225384615384616,15.316923076923077,16.408461538461538,{"y":17.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.31,4.2092307692307696,5.108461538461539,6.007692307692308,6.906923076923077,7.806153846153846,8.705384615384615,9.604615384615384,10.503846153846153,11.403076923076924,12.302307692307693,13.201538461538462,14.100769230769231,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.959,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.77,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.89,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.54,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.31,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >